309 related articles for article (PubMed ID: 30758229)
1. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
Hester EK; Astle K
Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
[No Abstract] [Full Text] [Related]
2. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
Ribera E
AIDS Rev; 2018; 20(4):179-186. PubMed ID: 30548024
[TBL] [Abstract][Full Text] [Related]
3. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.
Casado JL; Monsalvo M; Rojo AM; Fontecha M; Rodriguez-Sagrado MA
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):561-570. PubMed ID: 29775399
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
Boswell R; Foisy MM; Hughes CA
Ann Pharmacother; 2018 Jul; 52(7):681-689. PubMed ID: 29442543
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults.
Properzi M; Magro P; Castelli F; Quiros-Roldan E
Expert Rev Anti Infect Ther; 2018 Dec; 16(12):877-887. PubMed ID: 30392419
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
[TBL] [Abstract][Full Text] [Related]
10. Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
van Wyk J; Orkin C; Rubio R; Bogner J; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Matthews J; Wang R; Underwood M; Wynne B; Nascimento MC; Vandermeulen K; Gartland M; Smith KY
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):325-330. PubMed ID: 32675772
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir-rilpivirine coformulation.
Sun HY; Chang SY; Hung CC
Curr Opin HIV AIDS; 2018 Jul; 13(4):320-325. PubMed ID: 29553948
[TBL] [Abstract][Full Text] [Related]
12. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.
Capetti AF; Cossu MV; Paladini L; Rizzardini G
Expert Opin Pharmacother; 2018 Jan; 19(1):65-77. PubMed ID: 29246084
[TBL] [Abstract][Full Text] [Related]
14. Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection.
Durham SH; Chahine EB
Ann Pharmacother; 2021 Nov; 55(11):1397-1409. PubMed ID: 33593093
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.
Capetti AF; Astuti N; Cattaneo D; Rizzardini G
Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1183-1192. PubMed ID: 28854832
[TBL] [Abstract][Full Text] [Related]
17. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.
Ramos-Ruperto L; Arcos-Rueda MDM; de Miguel-Buckley R; Busca-Arenzana C; Mican R; Montejano R; Delgado-Hierro A; Montes ML; Valencia ME; Serrano L; Arribas JR; González J; Bernardino JI; Martín-Carbonero L
HIV Med; 2024 Jun; 25(6):684-691. PubMed ID: 38379338
[TBL] [Abstract][Full Text] [Related]
18. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting.
Casado JL; Monsalvo M; Fontecha M; Vizcarra P; Rodriguez MA; Vivancos MJ; Moreno S
HIV Res Clin Pract; 2019 Apr; 20(2):64-72. PubMed ID: 31303142
[No Abstract] [Full Text] [Related]
[Next] [New Search]
